Target Name: MIF
NCBI ID: G4282
Other Name(s): phenylpyruvate tautomerase | GLIF | macrophage migration inhibitory factor | Tyrosinase-related protein-2 | epididymis secretory sperm binding protein | Dopachrome-rearranging enzyme | Macrophage migration inhibitory factor (MIF) | Dopachrome isomerase | Phenylpyruvate tautomerase/L-dopachrome isomerase | Tyrosinase-related protein 2 | Glycosylation-inhibiting factor | Macrophage migration inhibitory factor | Phenylpyruvate tautomerase | DCF | L-dopachrome isomerase | Dopachrome tautomerase | TRP2 | Dopachrome delta-isomerase | MMIF | Dopachrome conversion factor | Dopachrome oxidoreductase | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | L-dopachrome-methyl ester tautomerase | DCT | Phenylpyruvic keto-enol isomerase | Dopachrome delta7,delta2-isomerase | TRP-2 | MIF_HUMAN | TRP-1 | Dopachrome keto-enol isomerase | L-dopachrome tautomerase | GIF

MIF as A Potential Drug Target Or Biomarker for Various Diseases

MIF (phenylpyruvate tautomerase), a gene encoding a protein involved in the metabolism of phenylpyruvate, a key metabolite of yeast, has recently been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders.

The identification of MIF as a potential drug target or biomarker comes from a study conducted by a research team led by Dr. Qun Liu, a professor of genetics at the University of California, San Diego. The study, published in the journal Nature Communications, identified MIF as a key regulator of the metabolism of phenylpyruvate, which is involved in the production of energy by the body's cells.

The study showed that MIF was highly expressed in various tissues and cells, including brain, muscle, and cancer cells. Additionally, the team found that MIF was involved in the regulation of phenylpyruvate metabolism, which is critical for the growth and survival of cells.

The implications of the MIF study are significant. The study suggests that MIF may be a promising drug target or biomarker for various diseases. \"Our findings suggest that MIF may be a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders,\" said Dr. Liu.

The study's findings have important implications for the development of new treatments for these diseases. For example, MIF may be a potential target for cancer, as it has been shown to be involved in the regulation of cell growth and metabolism. Additionally, MIF may be a potential biomarker for neurodegenerative disorders, as it is involved in the production of phenylpyruvate, which is a key metabolite involved in the development and progression of these disorders.

MIF may also be a potential target for psychiatric disorders, as it has been shown to be involved in the regulation of mood and anxiety. \"Our findings suggest that MIF may be involved in the regulation of mood and anxiety, which could make it a potential target for psychiatric disorders,\" said Dr. Liu.

The MIF study also has implications for our understanding of the underlying mechanisms of these diseases. \"Our study has identified a new pathway in the regulation of phenylpyruvate metabolism, which may be involved in the development and progression of various diseases,\" said Dr. Liu.

In conclusion, the MIF study has significant implications for our understanding of the regulation of phenylpyruvate metabolism and its potential as a drug target or biomarker for various diseases. Further research is needed to fully understand the role of MIF in these diseases and to develop new treatments based on these findings.

Protein Name: Macrophage Migration Inhibitory Factor

Functions: Pro-inflammatory cytokine involved in the innate immune response to bacterial pathogens (PubMed:15908412, PubMed:17443469, PubMed:23776208). The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense (PubMed:15908412, PubMed:17443469, PubMed:23776208). Counteracts the anti-inflammatory activity of glucocorticoids (PubMed:15908412, PubMed:17443469, PubMed:23776208). Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known (PubMed:11439086, PubMed:17526494). It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity (PubMed:11439086, PubMed:17526494)

More Common Targets

MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B